Bioventus Celebrates $6 Million of OSTEOAMP SELCT Fibers Sales Since Launch

You may recall reading that the OSTEOAMP family of solutions grew earlier this year with the March launch of OSTEOAMP SELECT Fibers. A new format of our flagship allograft offering, OSTEOAMP SELECT’s nanotextured fibers provide a conduit for cell migration and improved performance and handling. Surgeons have raved about the handling properties of OSTEOAMP SELECT and it has delivered positive patient outcomes the market has come to expect.

In addition to that, in the last six months, OSTEOAMP SELECT has grown to more than $6 million in sales for Bioventus.

“The growth factors in OSTEOAMP serve as a platform for our R&D team to develop brand extensions that provide greater flexibility and OSTEOAMP SELECT has turned into a tremendous offering for our sales and marketing teams to position with our distributors and surgeons,” said Megan Osorio, Vice President of Marketing, Surgical.

Bioventus colleagues celebrating the successful launch of OSTEOAMP SELECT Fibers. L to R: Larry Boyd, Jason Siegfried, Tony Bihl, Wendy Oakes, Greg Anglum, Megan Osorio, Andrew Hosmer, Leigh Ann Stradford, Brent Layne Artrip, Robin White, Ryan Koch, Scott Petrie, Bill Gentile and Alessandra Pavesio.

“The growth of OSTEOAMP mirrors the growth of our surgical orthobiologics business that was launched five years ago and I am proud of the work done by our commercial team this year. We plan to continue to build on this launch in 2020,” added Andrew Hosmer, Vice President of Sales, Surgical.

The surgical business continues to perform above budget, is up over prior year and is delivering double digit growth for Bioventus. More innovation for the business is coming this fall in the form of a 501K submission for SIGNAFUSE brand extension and next year with the planned Q3 launch of the SIGNAFUSE Bioactive Strip product.